Citadel Advisors
XENE icon

Citadel Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Citadel Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.62M Buy
131,000
+84,100
+179% +$3.87M ﹤0.01% 3664
2025
Q4 		$2.1M Buy
46,900
+17,600
+60% +$739K ﹤0.01% 5812
2025
Q3 		$1.18M Sell
29,300
-7,300
-20% -$257K ﹤0.01% 7180
2025
Q2 		$1.15M Buy
36,600
+30,100
+463% +$982K ﹤0.01% 6777
2025
Q1 		$218K Buy
6,500
+4,400
+210% +$167K ﹤0.01% 10288
2024
Q4 		$82.3K Sell
2,100
-1,500
-42% -$62K ﹤0.01% 11752
2024
Q3 		$142K Sell
3,600
-3,600
-50% -$145K ﹤0.01% 10637
2024
Q2 		$281K Sell
7,200
-3,300
-31% -$132K ﹤0.01% 9271
2024
Q1 		$452K Sell
10,500
-141,600
-93% -$6.51M ﹤0.01% 8613
2023
Q4 		$7.01M Buy
152,100
+131,200
+628% +$4.64M ﹤0.01% 3323
2023
Q3 		$714K Buy
20,900
+16,700
+398% +$625K ﹤0.01% 7299
2023
Q2 		$162K Sell
4,200
-3,300
-44% -$131K ﹤0.01% 10222
2023
Q1 		$268K Sell
7,500
-11,200
-60% -$414K ﹤0.01% 9603
2022
Q4 		$737K Sell
18,700
-6,400
-25% -$233K ﹤0.01% 7422
2022
Q3 		$906K Buy
25,100
+11,200
+81% +$403K ﹤0.01% 7208
2022
Q2 		$423K Sell
13,900
-4,200
-23% -$127K ﹤0.01% 9037
2022
Q1 		$553K Buy
18,100
+7,200
+66% +$216K ﹤0.01% 9144
2021
Q4 		$341K Sell
10,900
-64,600
-86% -$1.93M ﹤0.01% 10636
2021
Q3 		$1.15M Buy
75,500
+51,100
+209% +$888K ﹤0.01% 7787
2021
Q2 		$454K Buy
+24,400
New +$450K ﹤0.01% 10268

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's XENE Position: Q1 2026 in Review

Citadel Advisors increased its Xenon Pharmaceuticals (XENE) stake by 101% in Q1 2026, buying an estimated $61.4M and bringing the position to 2,652,990 shares worth $154M. The position accounts for 0.02% of the portfolio, ranked #573.

Citadel Advisors first reported a position in XENE in Q3 2018 and has held it in 31 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Citadel Advisors held 2,652,990 shares of Xenon Pharmaceuticals worth $154M as of Q1 2026.
  • Citadel Advisors bought 1,331,777 Xenon Pharmaceuticals shares in Q1 2026, an estimated $61.4M.
  • Xenon Pharmaceuticals made up 0.02% of Citadel Advisors's portfolio in Q1 2026, its #573 holding.
  • Citadel Advisors first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.